A Risk Prediction Score for Invasive Mold Disease in Patients with Hematological Malignancies

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Stanzani, Marta ^a   Lewis, Russell E ^a   Fiacchini, Mauro ^a   Ricci, Paolo ^a   Tumietto, Fabio ^a   Viale, Pierluigi ^a   Ambretti, Simone ^a   Baccarani, Michele ^a   Cavo, Michele ^a   Vianelli, Nicola ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTINEOPLASTIC AGENT; CORTICOSTEROID; FLUCONAZOLE; GALACTOMANNAN; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMYLOIDOSIS; APLASTIC ANEMIA; ARTICLE; BLOOD ANALYSIS; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CORRELATION ANALYSIS; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG MEGADOSE; FEMALE; FUNGUS CULTURE; HEALTH STATUS; HEMATOLOGIC MALIGNANCY; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; INCIDENCE; LYMPHOCYTOPENIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OCCUPATIONAL EXPOSURE; PREDICTION; PREDICTIVE VALUE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SCREENING TEST; SMOKING HABIT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; FEMALE; FUNGI; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MYCOSES; PREGNANCY; RETROSPECTIVE STUDIES; RISK; RISK FACTORS; YOUNG ADULT;

EID: 84884599469     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075531     Document Type: Article

References (49)

1. Pagano L, Caira M, Candoni A, Offidani M, Martino B, et al. (2010) Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 95: 644-650. doi:10.3324/haematol.2009.012054. PubMed: 19850903.
2. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA, (2007) Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 44: 531-540. doi:10.1086/510592. PubMed: 17243056.
3. Park BJ, Pappas PG, Wannemuehler KA, Alexander BD, Anaissie EJ, et al. (2011) Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis 17: 1855-1864. doi:10.3201/eid1710.110087. PubMed: 22000355.
4. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, et al. (2006) The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91: 1068-1075. PubMed: 16885047.
5. de Pauw BE, (2005) Between over- and undertreatment of invasive fungal disease. Clin Infect Dis 41: 1251-1253. doi:10.1086/496933. PubMed: 16206098.
6. de Pauw BE, Viscoli C, (2011) Managing invasive fungal infections: relying on clinical instincts or on a rational navigation system? J Antimicrob Chemother 66 (Suppl 1):: i55-i58. doi:10.1093/jac/dkr125. PubMed: 21177405.
7. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, et al. (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52: e56-e93. doi:10.1093/cid/cir073. PubMed: 21258094.
8. Herbrecht R, Bories P, Moulin JC, Ledoux MP, Letscher-Bru V, (2012) Risk stratification for invasive aspergillosis in immunocompromised patients. Ann N Y Acad Sci 1272: 23-30. doi:10.1111/j.1749-6632.2012.06829.x. PubMed: 23231711.
9. van der Velden WJ, Blijlevens NM, Donnelly JP, (2011) Genetic variants and the risk for invasive mould disease in immunocompromised hematology patients. Curr Opin Infect Dis 24: 554-563. doi:10.1097/QCO.0b013e32834ab1f4. PubMed: 21926619.
10. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, et al. (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46: 1813-1821. doi:10.1086/588660. PubMed: 18462102.
11. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, et al. (2007) Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 44: 1289-1297. doi:10.1086/514341. PubMed: 17443465.
12. Rogers TR, Slavin MA, Donnelly JP, (2011) Antifungal prophylaxis during treatment for haematological malignancies: are we there yet? Br J Haematol 153: 681-697. doi:10.1111/j.1365-2141.2011.08650.x. PubMed: 21504422.
13. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, et al. (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356: 348-359. doi:10.1056/NEJMoa061094. PubMed: 17251531.
14. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, et al. (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356: 335-347. doi:10.1056/NEJMoa061098. PubMed: 17251530.
15. Wingard JR, Ribaud P, Schlamm HT, Herbrecht R, (2008) Changes in causes of death over time after treatment for invasive aspergillosis. Cancer 112: 2309-2312. doi:10.1002/cncr.23441. PubMed: 18338758.
16. Moons KG, Royston P, Vergouwe Y, Grobbee DE, Altman DG, (2009) Prognosis and prognostic research: what, why, and how? BMJ 338: b375. doi:10.1136/bmj.b375. PubMed: 19237405.
17. Royston P, Moons KG, Altman DG, Vergouwe Y, (2009) Prognosis and prognostic research: Developing a prognostic model. BMJ 338: b604. doi:10.1136/bmj.b604. PubMed: 19336487.
18. Moons KG, Altman DG, Vergouwe Y, Royston P, (2009) Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ 338: b606. doi:10.1136/bmj.b606. PubMed: 19502216.
19. Ostrosky-Zeichner L, Pappas PG, Shoham S, Reboli A, Barron MA, et al. (2011) Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses 54: 46-51. doi:10.1111/j.1439-0507.2009.01756.x. PubMed: 19627509.
20. O'Brien SN, Blijlevens NM, Mahfouz TH, Anaissie EJ, (2003) Infections in patients with hematological cancer: recent developments. Hematology Am Soc Hematol Educ Program(2003): pp. 438-472.
21. Robin M, Porcher R, De Castro Araujo R, de Latour RP, Devergie A, et al. (2007) Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor. Biol Blood Marrow Transplant 13: 1304-1312. doi:10.1016/j.bbmt.2007.07.007. PubMed: 17950917.
22. Verweij PE, Kerremans JJ, Voss A, Meis JF, (2000) Fungal contamination of tobacco and marijuana. JAMA 284: 2875. doi:10.1001/jama.284.22.2869. PubMed: 11147983.
23. Grigg A, Slavin M, (2008) Minimizing the risk of recurrent or progressive invasive mold infections during stem cell transplantation or further intensive chemotherapy. Transpl Infect Dis 10: 3-12. doi:10.1111/j.1399-3062.2007.00259.x. PubMed: 17605732.
24. Post MJ, Lass-Floerl C, Gastl G, Nachbaur D, (2007) Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients. Transpl Infect Dis 9: 189-195. doi:10.1111/j.1399-3062.2007.00219.x. PubMed: 17511828.
25. Marr KA, Carter RA, Boeckh M, Martin P, Corey L, (2002) Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100: 4358-4366. doi:10.1182/blood-2002-05-1496. PubMed: 12393425.
26. El-Cheikh J, Castagna L, Wang L, Esterni B, Faucher C, et al. (2010) Impact of prior invasive aspergillosis on outcome in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. Leuk Lymphoma 51: 1705-1710. PubMed: 20629522.
27. Vazquez JA, Sobel JD, (1995) Fungal infections in diabetes. Infect Dis Clin North Am 9: 97-116. PubMed: 7769222.
28. Soubani AO, Qureshi MA, (2002) Invasive pulmonary aspergillosis following bone marrow transplantation: risk factors and diagnostic aspect. Haematologia (Budap) 32: 427-437. PubMed: 12803117.
29. Garcia-Vidal C, Upton A, Kirby KA, Marr KA, (2008) Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 47: 1041-1050. doi:10.1086/591969. PubMed: 18781877.
30. Lionakis MS, Kontoyiannis DP, (2003) Glucocorticoids and invasive fungal infections. Lancet 362: 1828-1838. doi:10.1016/S0140-6736(03)14904-5. PubMed: 14654323.
31. Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, León C, Alvarez-Lerma F, et al. (2005) Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care 9: R191-R199. doi:10.1186/cc3254. PubMed: 15987390.
32. Gavalda J, Len O, San Juan R, Aguado JM, Fortun J, et al. (2005) Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 41: 52-59. doi:10.1086/430602. PubMed: 15937763.
33. Mühlemann K, Wenger C, Zenhäusern R, Täuber MG, (2005) Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia 19: 545-550. PubMed: 15729382.
34. Allam MF, Del Castillo AS, Diaz-Molina C, Navajas RF, (2002) Invasive pulmonary aspergillosis: identification of risk factors. Scand J Infect Dis 34: 819-822.
35. Rondinelli PI, Ribeiro Kde C, de Camargo B, (2006) A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. J Pediatr Hematol/Oncol 28: 665-670. doi:10.1097/01.mph.0000212996.94929.0b.
36. Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, et al. (2006) Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 108: 2928-2936. doi:10.1182/blood-2006-03-008706. PubMed: 16720833.
37. Uys A, Rapoport BL, Anderson R, (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 12: 555-560. PubMed: 15197637.
38. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, et al. (1984) Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 100: 345-351. doi:10.7326/0003-4819-100-3-345. PubMed: 6696356.
39. Thursky K, Byrnes G, Grigg A, Szer J, Slavin M, (2004) Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 34: 115-121. doi:10.1038/sj.bmt.1704543. PubMed: 15156166.
40. Fukuda T, Boeckh M, Carter RA, Sandmaier BM, Maris MB, et al. (2003) Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 102: 827-833. doi:10.1182/blood-2003-02-0456. PubMed: 12689933.
41. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, et al. (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18: 295-304. doi:10.1097/00007890-197410000-00001. PubMed: 4153799.
42. Labbé AC, Su SH, Laverdière M, Pépin J, Patiño C, et al. (2007) High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation. Biol Blood Marrow Transplant 13: 1192-1200. doi:10.1016/j.bbmt.2007.06.013. PubMed: 17889356.
43. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, et al. (1980) Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69: 204-217. doi:10.1016/0002-9343(80)90380-0. PubMed: 6996481.
44. Parulekar W, Mackenzie R, Bjarnason G, Jordan RC, (1998) Scoring oral mucositis. Oral Oncol 34: 63-71. doi:10.1016/S1368-8375(97)00065-1. PubMed: 9659522.
45. Grow WB, Moreb JS, Roque D, Manion K, Leather H, et al. (2002) Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 29: 15-19. doi:10.1038/sj.bmt.1703332. PubMed: 11840139.
46. Mahieu LM, De Dooy JJ, Van Laer FA, Jansens H, Ieven MM, (2000) A prospective study on factors influencing Aspergillus spore load in the air during renovation works in a neonatal intensive care unit. J Hosp Infect 45: 191-197. doi:10.1053/jhin.2000.0773. PubMed: 10896797.
47. Cornet M, Levy V, Fleury L, Lortholary J, Barquins S, et al. (1999) Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation. Infect Control Hosp Epidemiol 20: 508-513. doi:10.1086/501661. PubMed: 10432165.
48. Berthelot P, Loulergue P, Raberin H, Turco M, Mounier C, et al. (2006) Efficacy of environmental measures to decrease the risk of hospital-acquired aspergillosis in patients hospitalised in haematology wards. Clin Microbiol Infect 12: 738-744. doi:10.1111/j.1469-0691.2006.01499.x. PubMed: 16842568.
49. Thio CL, Smith D, Merz WG, Streifel AJ, Bova G, et al. (2000) Refinements of environmental assessment during an outbreak investigation of invasive aspergillosis in a leukemia and bone marrow transplant unit. Infect Control Hosp Epidemiol 21: 18-23. doi:10.1086/501691. PubMed: 10656349.